Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Toxoplasmosis, Cerebral

ClinicalTrials.gov lists 13 trials for Toxoplasmosis, Cerebral or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 5.

MeSH D016781 Infections C01 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 2 Phase 2 3 Not applicable Not applicable 5 Observational Observational 3 Phase 1 Phase 1 2 Phase 2 Phase 2 3 Not applicable Not applicable 5 Observational Observational 3

Trials per phase

13 of the 13 trials are tagged with Toxoplasmosis, Cerebral itself; the rest are tagged with a narrower condition beneath it.

Get the Toxoplasmosis, Cerebral report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Toxoplasmosis, Cerebral trials start? (5)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 2
  • Not applicable
  • Observational

Top of scale: 1

2009: 1 trials (Observational 1) 2016: 1 trials (Not applicable 1) 2021: 1 trials (Phase 2 1) 2024: 1 trials (Observational 1) 2025: 1 trials (Observational 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2025 1
2024 1
2021 1
2016 1
2009 1

No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Toxoplasmosis, Cerebral trials in? (4)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 2 3
Not applicable 5
Observational 3

How many Toxoplasmosis, Cerebral trials are recruiting? (3)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 1
Completed 11
Unknown status 1

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Toxoplasmosis, Cerebral trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 5
Glaxo Wellcome 1
Pfizer 1

Which drugs are being tested for Toxoplasmosis, Cerebral? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Pyrimethamine 7
Calcium Leucovorin 5
Atovaquone 2
Sulfadiazine 1
Zidovudine 1

Interventions as named in the registry (4)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Clindamycin Gel 2
1% Azithromycin 1
Dexamethasone/Dexamethasone acetate 1
Clarithromycin XL 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which publications cover Toxoplasmosis, Cerebral? (16)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Performance Testing of PCR Assay in Blood Samples for the Diagnosis of Toxoplasmic Encephalitis in AIDS Patients from the French Departments of America and Genetic Diversity of Toxoplasma gondii: A Prospective and Multicentric Study. PLoS neglected tropical diseases 2016 Yes
Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2008 Yes
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Controlled clinical trials 1998 Yes
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997 Yes
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. The Journal of infectious diseases 1996 Yes

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages